BONESUPPORT – Publication of a clinical study highlighting Vancomycin release from CERAMENT® V in major hip surgery

Lund, Sweden, 08.00 CET, 22 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of new data on antibiotic release from CERAMENT® V in a clinical study. The study ‘Vancomycin elution from a biphasic ceramic bone substitute’ is published in Bone Joint Research (Bone Joint Res 2019; 8: 1-6).

Prof. Lars Lidgren from Lund University, senior author of the publication, commented: “This study represents an important milestone in understanding the antibiotic excretion kinetics of CERAMENT V in patients undergoing major hip surgery. The pharmacokinetic analyses showed initial high targeted local vancomycin levels, safe and low systemic levels and sustained and complete release from the ceramic bone substitute at one month”.

Prof. Sarunas Tarasevicius from the Lithuanian University of Health, Kaunas said “This is the first long-term pharmacokinetic report on vancomycin release from injectable CERAMENT V. It has already previously been proven that the plain ceramic bone graft substitute regenerates bone. The results of the study confirm that by combining initial high local antibiotic release with sustainable levels for a sufficient time, the  bone graft substitute should also be useful to eradicate and prevent bone infection”.

University of Lund performed the research in collaboration with M. Stravinskas, A. Vitkauskien and S. Tarasevicius from the Lithuanian University of Health at Kaunas, Lithuania.

The publication can be found in Bone Joint Res 2019; 8: 1-6:


BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit for more information.

BONESUPPORT and CERAMENT are registered trademarks.

For more information contact:

Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46(0) 46 286 53 70

Cord Communications
Charlotte Stjerngren
+46 (0)708 76 87 87

About Us

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform. The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth. BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at *CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States. BONESUPPORT™ and CERAMENT® are registered trademarks.